UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 566

Sortiert nach

Neoadjuvant Chemotherapy: Increasing Relevance in Cancer Management

Maurie M. Markman

2013

Link zum Volltext

Verfügbarkeit prüfen

Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges

Journal of oncology, 2010-01, Vol.2010, p.568938-20

2010

Link zum Volltext

Verfügbarkeit prüfen

Targeting the EGF Receptor for Ovarian Cancer Therapy

Journal of oncology, 2010-01, Vol.2010, p.414676-11

2010

Link zum Volltext

Verfügbarkeit prüfen

Molecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carcinoma

Journal of oncology, 2010-01, Vol.2010, p.740968-7

2010

Link zum Volltext

Verfügbarkeit prüfen

The Role of Dysregulated Glucose Metabolism in Epithelial Ovarian Cancer

Journal of oncology, 2010-01, Vol.2010, p.514310-13

2010

Link zum Volltext

Verfügbarkeit prüfen

A Current Review of Targeted Therapeutics for Ovarian Cancer

Journal of oncology, 2010-01, Vol.2010, p.149362-11

2010

Link zum Volltext

Verfügbarkeit prüfen

Repeated Intraperitoneal α-Radioimmunotherapy of Ovarian Cancer in Mice

Journal of oncology, 2010-01, Vol.2010, p.394913-394913

2010

Link zum Volltext

Verfügbarkeit prüfen

Downregulation of Epidermal Growth Factor Receptor Expression Contributes to α-TEA's Proapoptotic Effects in Human Ovarian Cancer Cell Lines

Journal of oncology, 2010-01, Vol.2010, p.824571-11

2010

Link zum Volltext

Verfügbarkeit prüfen

BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer

Journal of oncology, 2010-01, Vol.2010, p.891059-9

2010

Link zum Volltext

Verfügbarkeit prüfen

Antivascular Therapy for Epithelial Ovarian Cancer

Journal of oncology, 2010-01, Vol.2010, p.372547-16

2010

Link zum Volltext

Verfügbarkeit prüfen

Disrupting Ovarian Cancer Metastatic Colonization: Insights from Metastasis Suppressor Studies

Journal of oncology, 2010-01, Vol.2010, p.286925-7

2010

Link zum Volltext

Verfügbarkeit prüfen

The remarkable “paclitaxel story”: How many chapters remain to be written?

Gynecologic oncology, 2008-10, Vol.111 (1), p.7-8

Markman, Maurie, MD

2008

Link zum Volltext

Verfügbarkeit prüfen

Clinical Features of Hypersensitivity Reactions to Carboplatin

Journal of clinical oncology, 1999-04, Vol.17 (4), p.1141-1145

1999

Link zum Volltext

Verfügbarkeit prüfen

Society of Gynecologic Oncologists Position Paper: Breast Cancer Care

Gynecologic oncology, 2008-07, Vol.110 (1), p.7-12

2008

Link zum Volltext

Verfügbarkeit prüfen

Nutritional Intervention in Ovarian Cancer: Failure to Appreciate the Fundamental Distinction Between a Prognostic and a Predictive Clinical Parameter

Clinical ovarian cancer and other gynecologic malignancies, 2010-05, Vol.3 (1), p.7-8

Markman, Maurie, MD

2010

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy-induced neutropenia and fever in patients receiving cisplatin-based chemotherapy for ovarian malignancy

Gynecologic oncology, 1991, Vol.40 (1), p.17-20

1991

Link zum Volltext

Verfügbarkeit prüfen

Intraperitoneal antineoplastic drug delivery: rationale and results

The lancet oncology, 2003-05, Vol.4 (5), p.277-283

Markman, Maurie

2003

Link zum Volltext

Verfügbarkeit prüfen

Cardio-Oncology: mechanisms of cardiovascular toxicity [version 1; peer review: 2 approved]

F1000 research, 2018, Vol.7, p.113-113

2018

Link zum Volltext

Verfügbarkeit prüfen

Ovarian cancer

The Lancet (British edition), 2009-10, Vol.374 (9698), p.1371-1382

2009

Link zum Volltext

Verfügbarkeit prüfen

Cardio-oncology: management of cardiovascular toxicity [version 1; peer review: 2 approved]

F1000 research, 2019, Vol.8, p.120

2019

Link zum Volltext

Verfügbarkeit prüfen

Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial Design

Journal of clinical oncology, 2004-08, Vol.22 (15), p.3120-3125

2004

Link zum Volltext

Verfügbarkeit prüfen

Managing taxane toxicities

Supportive care in cancer, 2003-03, Vol.11 (3), p.144-147

MARKMAN, Maurie

2003

Link zum Volltext

Verfügbarkeit prüfen

Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer

Journal of clinical oncology, 2010-08, Vol.28 (22), p.3570-3576

2010

Link zum Volltext

Verfügbarkeit prüfen

Safety Issues in Using Complementary and Alternative Medicine

Journal of clinical oncology, 2002-09, Vol.20 (suppl 1), p.39s-41s

MARKMAN, Maurie

2002

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group

Journal of clinical oncology, 2001-02, Vol.19 (4), p.1001-1007

2001

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 566

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(401)
Mit Volltextzugriff
(539)

Publikationsform

Artikel
(414)
Buchkapitel
(139)
Bücher
(8)
Berichte
(5)

Sprache

Englisch
(566)
Japanisch
(56)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(490)
Life Sciences & Biomedicine
(487)
Oncology
(448)
Humans
(360)
Female
(265)
Biological And Medical Sciences
(156)
Medical Sciences
(155)
Ovarian Neoplasms - Drug Therapy
(142)
Middle Aged
(140)
Aged
(120)
Obstetrics & Gynecology
(113)
Pharmacology. Drug Treatments
(109)
Chemotherapy
(104)
Adult
(96)
Antineoplastic Agents
(90)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(79)
Ovarian Cancer
(61)
Tumors
(55)
Cisplatin - Administration & Dosage
(51)
Antineoplastic Agents - Administration & Dosage
(50)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Neoadjuvant Chemotherapy: Increasing Relevance in Cancer Management

Targeting the Epidermal Growth Factor Receptor in Epithelial Ovarian Cancer: Current Knowledge and Future Challenges

Targeting the EGF Receptor for Ovarian Cancer Therapy

Molecular Abnormalities in Ovarian Cancer Subtypes Other than High-Grade Serous Carcinoma

The Role of Dysregulated Glucose Metabolism in Epithelial Ovarian Cancer

A Current Review of Targeted Therapeutics for Ovarian Cancer

Repeated Intraperitoneal α-Radioimmunotherapy of Ovarian Cancer in Mice

Downregulation of Epidermal Growth Factor Receptor Expression Contributes to α-TEA's Proapoptotic Effects in Human Ovarian Cancer Cell Lines

BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer

Antivascular Therapy for Epithelial Ovarian Cancer

Disrupting Ovarian Cancer Metastatic Colonization: Insights from Metastasis Suppressor Studies

The remarkable “paclitaxel story”: How many chapters remain to be written?

Clinical Features of Hypersensitivity Reactions to Carboplatin

Society of Gynecologic Oncologists Position Paper: Breast Cancer Care

Nutritional Intervention in Ovarian Cancer: Failure to Appreciate the Fundamental Distinction Between a Prognostic and a Predictive Clinical Parameter

Chemotherapy-induced neutropenia and fever in patients receiving cisplatin-based chemotherapy for ovarian malignancy

Intraperitoneal antineoplastic drug delivery: rationale and results

Cardio-Oncology: mechanisms of cardiovascular toxicity [version 1; peer review: 2 approved]

Ovarian cancer

Cardio-oncology: management of cardiovascular toxicity [version 1; peer review: 2 approved]

Duration of Response to Second-Line, Platinum-Based Chemotherapy for Ovarian Cancer: Implications for Patient Management and Clinical Trial Design

Managing taxane toxicities

Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer

Safety Issues in Using Complementary and Alternative Medicine

Suchergebnisse filtern